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Thelocalrenin-angiotensinsystemispresentinthepituitary.WeinvestigatedtheeﬀectsofangiotensinsonGH3lactosomatotroph
cells proliferation in vitro and the involvement of p44/42 and p38 MAPK inhibitors in the growth-regulatory eﬀects of
angiotensins. Materials and Methods. Cell viability using the Mosmann method and proliferation by the measurement of BrdU
incorporation during DNA synthesis were estimated. Results. Ang II and ang IV decreased the viability and proliferation of GH3
cells. Inhibitor of p44/42 MAPK attenuated the eﬀects of ang II on cell viability and proliferation but did not aﬀect the ang 5-
8-dependent actions. Inhibitor of p38 MAPK prevented the decrease in the number of GH3 cells in ang-II- and ang-IV-treated
groups. Conclusions. The growth-inhibitory eﬀect of ang II is possibly mediated by the p44/42 MAPK. The p38 MAPK appears to
mediate the inhibitory eﬀects of both ang II and ang 5–8 upon cell survival.
1.Introduction
The existence of intrinsic tissue angiotensin-generating bio-
enzymatic cascades, independent of the classical circulating
renin-angiotensin system (RAS), has been established in
several organs including heart [1, 2], blood vessels [3, 4],
brain [5], kidney [6, 7], endocrine system (adrenals, thymus,
ovary, testis, prostate) [8], gastrointestinal tract [9], liver,
pancreas [10], as well as adipose and hematopoietic tissues
(reviewed in details by Leung [11]). Angiotensin II (ang II),
the main bioactive peptide of RAS, is cleaved by aminopep-
tidase A (APA) into a shorter peptide ang III (ang 2–8) [12].
AminopeptidaseN(APN)is,inturn,responsibleforthecon-
version of ang III into ang IV (ang 3–8) [13, 14]. The sub-
sequent degradation of ang IV leads to the formation of ang
4–8 and ang 5–8. Locally synthesized ang II has been deﬁned
to act as an autocrine and paracrine growth factor in many
tissues [15] including vascular smooth muscle [16], heart
muscle [17], adrenal cortex [18, 19], renal mesangium [20]
and epithelium [21], or prostatic stroma [22]. Moreover, the
increasing lines of evidence indicate the additional eﬀects of
ang II derivatives on cellular growth. Ang III and ang IV have
been demonstrated to inhibit the growth of the androgen-
independent human prostate cancer line in vitro [23]. Ang
IV was additionally shown to induce neurite outgrowth and
to stimulate proliferation in the uterine endometrium [24],
adrenal zona glomerulosa [25], prostatic epithelium [26],
and vascular endothelium [27]. Few attempts have been
undertaken to understand the physiological functions of ang
4–8 or ang 5–8, and most authors consider the ang IV
derivatives to be biologically inactive.
Angiotensin peptides act via at least three angiotensin
receptors, designated AT1, AT2, and AT4. Ang IV binds pre-
ferentially to the speciﬁc receptor subtype called AT4, which
shows poor aﬃnity to ang IV precursors. Besides an intra-
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G-protein-coupled receptors, angiotensins are able to mod-
ulate the activity of the tyrosine-kinase-receptor- (TKR-)
linked pathways, including mitogen-activated protein kinas-
es (MAPKs) [28–33]. MAPKs belong to the family of protein
serine/threonine kinases, and they have been divided into
three main groups: the extracellular-regulated kinases 1/2
(ERK1/2 or MAPK p44/42), MAP p38, and the c-jun-N-
terminal kinases (JNK). ERK1/2 is typically activated by the
growth factors and cytokines via TKR and its downstream
eﬀectors following Ras, Raf, and mitogen-activated protein
kinase kinase (MAPKK or MEK) [34, 35]. This group is
known to mediate mitogenic and antiapoptotic eﬀects. MAP
p38,andJNKrespondtotheproinﬂammatorycytokines,cel-
lular stress, heat shock, and hyperosmolarity and are usually
connectedwithantiproliferationandpromotionofapoptosis
[36, 37]. The well-deﬁned eﬀects of angiotensin peptides via
MAPKs imply the role of RAS in the pathogenesis of various
disorders, such as vascular hypertrophy and remodeling or
hypertrophy of renal proximal tubular cells leading to the
tubulointerstitial ﬁbrosis [38–40]. Ang II has been also
suggested to aﬀect the development of some neoplasms in-
cluding acute myeloid leukemia, prostate cancer, pancreatic
c a n c e r ,o rC 6g l i o m ao fr a t[ 41–44].
The existence of an intrinsic angiotensin-generating sys-
tem in the anterior pituitary has been provided by recent
immunohistochemical and molecular studies [45–47]. They
have shown that the components of RAS including pep-
tides, receptors, and enzymes are present in all types of
the hormone-secreting anterior pituitary cells, whereas the
speciﬁc-binding sites for ang II are localized mainly on lacto-
tropes. Locally produced ang II is known to aﬀect the release
of anterior pituitary hormones in a paracrine and autocrine
manner. This peptide is known to promote secretion of pro-
lactin(PRL)andadrenocorticotropichormone(ACTH)and,
to a lesser extent, growth hormone (GH) and luteinizing
hormone (LH) [48]. Earlier in vitro and in vivo studies have
also suggested the involvement of RAS in regulation of
lactotropes proliferation and the engagement of this system
in pathogenesis of estrogen-induced PRL-secreting adenoma
[49]. Nevertheless, there are no reports on the postreceptor
mechanism connected with angiotensin action on the lac-
totropiccellgrowth.Inthepresentstudy,weemployedlacto-
somatotroph GH3 cells in order to determine the inﬂuences
of ang II and its derivatives, ang IV, and ang 5–8, on anterior
pituitary tumor cell proliferation. Using the inhibitors of two
MAPK cascades, we also examined the potential association
of MAPK p44/42 and MAPK p38 with eﬀects of angiotensin
peptides.
2.MaterialsandMethods
2.1. Materials. The chemicals used in present experiments
were obtained from the following sources: angiotensin II
(ang II, Sigma), angiotensin IV (ang IV, Bachem), angiot-
ensin 5–8 (ang 5–8, Bachem), PD98059 (Sigma), SB203580
(Sigma), dimethyl sulfoxid, DMSO, C2H6OS (Merck), nutri-
ent mixture F-10 (Ham) (Sigma), sodium bicarbonate,
NaHCO3 (Sigma), penicillin/streptomycin solution (Sigma),
fetal bovine serum, FBS (Sigma), horse serum (Sigma), tryp-
sin-EDTA (Sigma).
2.2. Cell Culture. The rat lactosomatotroph tumor cell line
GH3(CCL-82.1)wasobtainedfromATCC,LGCPromochem.
GH3cellsareaclonalstrainofratpituitary tumorcells.They
have many properties common to both normal lactotropes
and lactosomatotropes, being thus valuable model for the
investigations of functions of PRL-secreting cells. Continu-
ous GH3 cell culture was maintained in culture ﬂasks (Nunc
Eas Y Flask 25cm2, NUNC). All the cells were grown in
Ham’s F-10 medium supplemented with 1.2g/L sodium
bicarbonate, 100U/mL penicillin and 100μg/mL strepto-
mycin solution, 15% heat-inactivated horse serum and 2.5%
heat-inactivated fetal bovine serum at 37◦C and in a humidi-
ﬁed atmosphere of 95% air and 5% CO2. Every 7 days, the
cells were harvested after 2min incubation at 37◦C in the
presence of trypsin-EDTA (0.05 or 0.02%, resp.) in Hanks
balanced solution. The cells were washed twice in complete
F-10 medium and, after the last centrifugation seeded at
1 ×105 cells in 5mL of fresh medium.
2.3. Cell Viability Study. The cells were subjected to the tryp-
sinization process and then suspended at 4 × 105/mL in
complete F-10 medium. 50μLa l i q u o t so fc e l ls u s p e n s i o n
(2 × 104 cells) were placed in the wells of plastic 96-well
culture plates (96 Cell Culture Cluster Dish, Costar; Nun-
clon, Microwell Plates, NUNC). After 12hr period of prein-
cubation (5% CO2,3 7 ◦C, 95% humidity), the tested sub-
stances were added to the appropriate wells: in experiment
(1), ang II or ang IV at ﬁnal concentrations of 10−6 M,
10−8 M, 10−10 M, or 10−12 M; 10−8 Ma n gI Io r1 0 −8 Ma n g
I V+a m a s t a t i na tﬁ n a lc o n c e n t r a t i o n so f1 0 −5 M, 10−6 M,
or 10−7 M. The appropriate volume of the culture medium
was added to the wells of control group and to the wells
with one tested substance to the ﬁnal volume 200μLi ne a c h
well. In experiment (2), ang II at ﬁnal concentration of
10−8 M, ang 5–8 at ﬁnal concentration of 10−10 M, PD98059
at ﬁnal concentration of 10−5M, SB203580 at ﬁnal concen-
tration of 10−5 M; 10−8 Ma n gI Io r1 0 −10 Ma n g5 – 8+
10−5 M PD98059; 10−8 Ma n gI Io r1 0 −10 Ma n g5 – 8+
10−5 M SB203580. Both PD98059 and SB203580 were dis-
solved in the DMSO/medium solution, in the proportion
DMSO:medium 37:63 for PD98059 and 1:9 for SB98059.
Since DMSO is known to aﬀect cellular viability, the appro-
priate solution of culture medium with DMSO was added to
the wells of control group and to the wells with ang II or ang
5–8 alone, to obtain the ﬁnal DMSO concentration equiv-
alent to that in the PD98059- or SB203580-treated groups.
Finally, the appropriate volume of the culture medium was
added to the wells of control group and to the wells with one
tested substance, to the ﬁnal volume 200μLi ne a c hw e l l .
After 72hrs of incubation (5% CO2,3 7 ◦C, 95% humid-
ity),cellviabilitywasestimatedusingthemodiﬁedMosmann
method, following the procedure recommended by the
producer of the kit (EZ4Y, Easy for You, the 4th Gener-
ation Non Radioactive Cell Proliferation and Cytotoxicity
Assay, Biomedica Gruppe, Austria, Bellco Biomedica Poland).The Scientiﬁc World Journal 3
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Figure 1: The inﬂuence of 72hr treatment with angiotensin II (AII) and angiotensin IV (AIV) on the cellular viability in the lactosomatot-
rophGH3cellculture.X axis:absolutevaluesoftheopticaldensity(OD),auxiliaryaxis():ODintheparticularangiotensin-treatedgroups
expressed asthepercentage oftheoptical densitymeasuredat 450nmofunstimulated cells (control(C) =100%).X±SEM; ∗P<0.05 versus
C.
The optical density (OD) of each sample was measured by a
microplate reader at 450nm.
2.4. Cell Proliferation Study. After trypsinization process, the
cellsweresuspendedat3×105/mLincompleteF-10medium.
50μL aliquots of cell suspension (1.5×104 cells) were placed
in the wells of plastic 96-well culture plates (96 Cell Culture
Cluster Dish, Costar; Nunclon, Microwell Plates, NUNC).
After 12hrs period of preincubation (5% CO2,3 7 ◦C, 95%
humidity), the tested substances were added to the appro-
priate wells: in experiment (1), ang II, ang IV, or ang 5–8 at
ﬁnal concentrations of 10−12 M, 10−10 M, 10−8 M, or 10−6 M.
The appropriate volume of the culture medium was added to
the wells of control group the ﬁnal volume 100μLi ne a c h
well. In experiment (2), ang II at ﬁnal concentration of
10−8 M, ang 5–8 at ﬁnal concentration of 10−10 M, PD98059
at ﬁnal concentration of 10−5 M, SB203580 at ﬁnal concen-
tration of 10−5 M; 10−8 Ma n gI Io r1 0 −10 Ma n g5 – 8+
10−5 M PD98059; 10−8 Ma n gI Io r1 0 −10 Ma n g5 – 8+
10−5 M SB203580. Both PD98059 and SB203580 were dis-
solved in the DMSO/medium solution, in the proportion
DMSO:medium 37:63 for PD98059 and 1:9 for SB98059.
Since DMSO is known to aﬀect cellular proliferation, the
appropriate solution of culture medium with DMSO was
a d d e dt ot h ew e l l so fc o n t r o lg r o u pa n dt ot h ew e l l sw i t ha n g
II or ang 5–8 alone, to obtain the ﬁnal DMSO concentration
equivalent to that in the PD98059- or SB203580-treated
groups. Finally, the appropriate volume of the culture med-
ium was added to the wells of control group and to the wells
with one tested substance, to the ﬁnal volume 100μLi ne a c h
well.
The cells were cultured in the presence of the tested sub-
stances for 72hrs (5% CO2,3 7 ◦C, 95% humidity). After
68hrsofincubation,10μLBrdUlabelingsolution(ﬁnalcon-
centration: 10μM BrdU) was added to each well, and the
cells were reincubated for additional 4hrs, necessary for
pyrimidine analogue BrdU to incorporate into DNA of
proliferating cells. Then, cell proliferation was measured fol-
lowing the procedure recommended by the producer of the
kit (Cell Proliferation ELISA, BrdU (colorimetric), colori-
metric immunoassay for the quantiﬁcation of cell prolif-
eration, based on the measurement of BrdU incorporation
during DNA synthesis, a nonradioactive alternative to the
[3H]-thymidine incorporation assay, Roche). The optical
density (OD) of each sample was measured by a microplate
reader at 450nm.
2.5. Statistical Evaluation. Data are given as the absolute val-
ues of extinction and as the percentage of the optical density
(OD) measured at 450nm of unstimulated cells (= 100%)
and represents 8–10 diﬀerent measurements ± SD. The nor-
mality of distribution of the results was examined by the
Student test. Comparisons of individual groups were evalu-
ated by analysis of variance (ANOVA). Diﬀerences were con-
sidered signiﬁcant if P<0.05.
3. Results
As demonstratedinFigure 1, the treatmentof GH3 cellswith
angIIatconcentrationsof10−6 M,10−8 M,10−10 Mandwith
ang IV at concentrations 10−8 Ma n d1 0 −10 Mr e s u l t e di na n
inhibition of the total culture viability. Since culture viability
has been proved as parallel to the number of metabolically
active cells, these data imply the examined angiotensin pep-
tidesdecreasethenumberofGH3cellsinculture.Amastatin,
the inhibitor of aminopeptidases A and M, abolished—
partiallyatconcentrationsof10−6 M–10−7 Mandcompletely
at concentration of 10−5 M—the inhibitory eﬀect of ang
IV (Figure 2). In contrast, pretreatment with amastatin did
not prevent the decrease in the number of GH3 cells in
response to ang II (Figure 2). Determination of the cellular
proliferationusingBrdUincorporationmethodrevealedthat
ang II at concentrations 10−6 M, 10−8 M, 10−12 M, and ang4 The Scientiﬁc World Journal
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Figure 3: The inﬂuence of 72-hrs treatment with angiotensin II (AII), angiotensin IV (AIV), and angiotensin 5–8 (A5–8) on the cellular
proliferation expressed as BrdU incorporation in the lactosomatotroph GH3 cell culture. X axis: absolute values of the optical density (OD),
auxiliary axis (): OD in the particular angiotensin-treated groups expressed as the percentage of the optical density measured at 450nm of
unstimulated cells (control (C) = 100%). X± SEM; ∗P<0.05 versus C.
IV at concentration 10−8 M decreased also BrdU uptake
in GH3 culture (Figure 3). Antiproliferative eﬀect has been
additionally shown with respect to the ang IV degradation
product, ang 5–8 (Figure 3).
In order to examine an involvement of two MAPK
pathways,thep44/42MAPKandp38MAPK,intheobserved
eﬀects of angiotensin peptides in GH3 cell culture, we used
the speciﬁc inhibitor of MEK phosphorylation PD98059
and the speciﬁc inhibitor of p38 MAPK SB203580. Both
inhibitors were used at concentrations of 10μM( 1 0 −5 M),
the level at which they have been proved to block the acti-
vity of MAPK p44/42 and MAPK p38. We revealed that
PD98059 attenuated the inhibitory eﬀects of ang II on both
cell viability and proliferation but did not aﬀect the ang-5–
8-dependent actions (Figures 6 and 7). SB203580 partially
prevented the decrease in the number of GH3 cells in both
ang-II- and ang-IV-treated groups (Figure 4) but did not
impair the antiproliferative eﬀects of the peptides (Figure 5).
Moreover, p38 MAPK inhibitor alone lowered basal number
and proliferation of GH3 cells (Figures 4 and 5).The Scientiﬁc World Journal 5
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Figure 4: The inﬂuence of p38 MAPK inhibitor SB203580 at concentration 10−5 M on angiotensin-II-(AII-) and angiotensin-5–8-(A5–8-)
induced decrease of the cellular viability in the lactosomatotroph GH3 cell culture. X axis: absolute values of the optical density (OD),
auxiliary axis (): OD in the particular groups expressed as the percentage of the optical density measured at 450nm of unstimulated cells
(control (C) = 100%). X± SEM; ∗P<0.05 versus C, ∗∗P<0.05 versus AII, ∗∗∗P<0.05 versus A5–8.
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Figure 5: The inﬂuence of p38 MAPK inhibitor SB203580 at concentration 10−5 M on angiotensin-II-(AII-) and angiotensin-5–8-(A5–8-)
induced decrease of the BrdU incorporation into lactosomatotroph GH3 cells. X axis: absolute values of the optical density (OD), auxiliary
axis (): OD in the particular groups expressed as the percentage of the optical density measured at 450nm of unstimulated cells (control
(C) = 100%). X± SEM; ∗P<0.05 versus C, ∗∗P<0.05 versus AII, ∗∗∗P<0.05 versus A5–8.
4. Discussion
Numerous cytokines, growth factors, and hormones have
been found to be implicated in the pituitary tumor develop-
ment. Phosphorylation of the MAP kinases via the receptors
with intrinsic tyrosine kinase activity has been deﬁned as
essential to the growth-regulatory eﬀects of many factors.
Some of the TKRs may be coexpressed with their ligands,
thus forming the intrapituitary autocrine loops that stimu-
late adenoma cell growth. The pituitary RAS is possibly one
of these regulatory loops, as the components of this system
including precursors, enzymes, and the receptors have been
identiﬁed within the cells of various anterior pituitary tu-
mors as well as in the cells of lactosomatotrop GH3 line. On
the other hand, the involvement of angiotensin peptides in
the control of cellular proliferation within anterior pituitary
has previously been demonstrated.
We found that all angiotensin peptides investigated, ang
II, ang IV, and ang 5–8, inhibited cellular proliferation, and
decreased the number of viable cells in GH3 cell culture. Our
study is not the ﬁrst to demonstrate antiproliferative eﬀects
of angiotensins. Ang II has been found to decrease the cell
growth in primary culture of rat adrenal glomerulosa cells
and the bFGF-induced proliferation of bovine adrenal fasci-
culate cells [50, 51]. Ławnicka et al. revealed the inhibitory
actions of ang II, ang III, and ang IV on the growth of DU-
145 human prostate cancer cell line in vitro [23]. On the
other hand, the results of the present study seem to stay in
opposition with the earlier data, showing the stimulatory
eﬀectofang IIand angIVon normal pituitary lactotrophsor
estrogen induced prolactinomas either in vivo and in vitro
[49, 52–54]. The discrepancy between our results and the
results of previous experiments may be possibly explained
by the application of diﬀerent experimental models. First,6 The Scientiﬁc World Journal
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Figure 7:Theinﬂuenceofp44/42MAPKinhibitorPD98059atconcentration10−5 Monangiotensin-II-(AII-)andangiotensin-5–8-(A5–8-)
induced decrease of the BrdU incorporation into lactosomatotroph GH3 cells. X axis: absolute values of the optical density (OD), auxiliary
axis (): OD in the particular groups expressed as the percentage of the optical density measured at 450nm of unstimulated cells (control
(C) = 100%). X± SEM; ∗P<0.05 versus C, ∗∗P<0.05 versus AII, ∗∗∗P<0.05 versus A5–8.
the estrogen-induced-prolactinoma cells and lactosoma-
totroph GH3 cells, in spite of many similarities, represent
the distinct cell types certainly diﬀering at the genomic level.
Second, under in vivo conditions, the growth-promoting
eﬀects of angiotensins may be mediated by their involvement
in the control of angiogenesis.
In GH3 cell culture, the inhibitory eﬀect of ang IV on the
cell viability is completely abolished by amastatin, whereas
this inhibitor of aminopeptidases did not inﬂuence the ang-
II-induced eﬀect. The latter ﬁnding suggests that growth-
inhibitory action of ang II in GH3 cell culture does not
depend on its conversion into smaller fragments. With res-
pect to ang IV, the observed abolition of its eﬀects by amas-
tatin is rather unexpected. Amastatin has been demonstrated
to inactivate selectively APA and APN, the enzymes respon-
sible for the N-terminal degradation of ang II and ang III,
respectively [55–57]. However, our results suggest that the
action of this aminopeptidases inhibitor may be extended on
the inactivation of other than APA/APN enzymes, including
ang IV degrading peptidases. Presuming such an activity
of amastatin, we would hypothesize that growth-inhibitory
eﬀect of ang IV in GH3 cell culture is determined by its pre-
vious conversion into the smallest peptides. Such a mecha-
nism is highly probable in the context of the reported above
antiproliferative eﬀect of ang 5–8 in the culture of GH3 cells.
For our best knowledge, the present study is the ﬁrst one
demonstrating the ability of ang 5–8 to regulate cellular pro-
liferationandthepossibleactionofangIVviaitsdegradation
products.
Phosphorylation of the MAP kinases via the receptors
with intrinsic tyrosine kinase activity has been deﬁned as
essential to the growth-regulatory eﬀects of many factors.The Scientiﬁc World Journal 7
The earlier papers from our laboratory showed the stimu-
lation of global TRK activity in rat anterior pituitary glands
and the estrogen-induced rat pituitary prolactinomas by ang
II and ang IV [52, 53] and by ang III and ang 1–7 as well
[58, 59]. The present study revealed that the inhibitor of the
p44/42 MAPK pathway, PD98059, abolished the inhibitory
eﬀects of ang II on both BrdU incorporation and total cell
viability, but did not aﬀect the ang 5–8-dependent actions.
These data suggest that, in GH3 cell culture, ERK phospho-
rylation may be essential for the ang-II-induced antiprolif-
eration. In contrast to ang II, ang 5–8 appears to decrease
proliferation and total viability of the GH3 cells indepen-
dently on the MEK-ERK phosphorylation. Nevertheless, our
results do not exclude regulatory inﬂuence of ang 5–8 upon
the p44/42 MAPK activity via other mechanisms, that is,
MAPK phosphatases (MKP) inactivation.
An involvement of p44/42 MAPK in the antiproliferative
eﬀects may seem surprising from the point of view of earlier
studies.TheactivationofERK1/2wascriticalforthegrowth-
promoting actions of ang II in cardiac ﬁbroblasts or prostate
c a n c e rc e ll si nc u l t u r e s[ 41]. These MAPKs were also demon-
strated to participate in the ang-IV-dependent mitogenic
eﬀects in cultured lung endothelial cells [27]. Similar results
have been obtained with respect to the lactotroph and lac-
tosomatotroph cells. ERK1/2 were shown to mediate the
bFGF-induced proliferation in PRL lactotroph cells and
enriched lactotropes [60]. Furthermore, the inhibitory eﬀect
of somatostatin on the GH3 cell cycle progression seemed
to be dependent on the decrease in MAPK activity [61, 62].
However, there are also reports on the association of ERK
cascade with antiproliferative eﬀects. In GH3 cell culture,
both thyrotropin-releasing hormone (TRH) and epidermal
growth factor (EGF) induced ERK activity that correlated
with reduced DNA synthesis and concomitant diﬀerenti-
ation of lactosomatotropes into lactotropes [63, 64]. Otis
et al. [50] revealed that ang-II-stimulated MAPK p44/42
phosphorylation led to an increase in p27Kip1 expression
and to the subsequent inhibition of cellular proliferation in
cultured rat glomerulosa cells. Later studies indicated that
ang-II-induced inhibition of proliferation of rat adrenal
glomerulosa cells involved both p42/p44 MAPK and p38
MAPK activation [65]. The identical mechanism of action
was responsible for ang-II-mediated inhibition of cell cycle
progression in renal proximal tubular cells [40]. At the end,
ang-II-induced ERK activity caused the hypertrophy of
vascular smooth muscle cells (VSMCs), as opposed to the
platelet-derived growth-factor-(PDGF-) dependent cell pro-
liferation [66].
The whole of former studies suggest that the same intra-
cellular pathways may be shared between proliferation and
diﬀerentiation [67]. It has been demonstrated that mitogenic
eﬀects usually appeared in response to the transient ERK
activity, whereas the sustained MAPK induction led to anti-
proliferative responses [68–71]. In the view of these results,
we might speculate that strong persistent activation of an
unidentiﬁed receptor by ang II may result in the sustained
ERK activation and subsequent inhibition of cellular pro-
liferation in GH3 cell culture. Furthermore, in context of
previously reported mitogenic properties of ERK-dependent
signals in GH3 cells, our results strengthen the hypothesis
that regulation of the cellular growth and by MAPK is
possibly cell speciﬁc and dependent on the stimulus [72].
As reported above, inhibitor of p38 MAPK blunted the
ang-II- and ang-5–8-induced decrease in number of the
viable GH3 cells. In contrast, SB203580 did not aﬀect the
inhibitory eﬀects of angiotensin peptides on BrdU incorpo-
ration. Ourstudyclearlyindicates thatMosmann’s andBrdU
incorporation techniques do not provide the parallel results.
Indeed, it should be mentioned, that Mosmann’s method
estimates the total number of viable cells, but does not dis-
criminate between the eﬀects depending on the changes in
proliferation, necrosis or apoptosis. In contrast, BrdU-incor-
poration serves as a direct mitotic index, and it reﬂects the
changes concerning only the cellular proliferation. All these
ﬁndings suggest that p38 MAPK mediates neither the anti-
proliferative eﬀects of ang II nor ang 5–8, but it is possibly
connected with inhibitory eﬀects of both peptides upon the
cell survival, that is, via the induction of apoptosis. This
presumption is highly probable in the context of previ-
ously reported association of the p38 MAPK pathway with
apoptosis [73, 74]. Furthermore, bromocriptine-induced
p38 MAPK activation was implicated in apoptosis of the
bromocriptine-treated GH3 cells [75].
Inhibitory eﬀect of SB203580 on the basal cell number
and proliferation is intriguing. Nevertheless, it is worth
recalling that inhibitors of p38 MAPK are known to block
arachidonic acid metabolism in several cell types [72, 76].
On the other hand, one of the arachidonic acid derivatives,
12-lipooxygenase product 12-hydroxyeikosatetraenoic acid,
has been found to increase cellular proliferation [77]. There
is also possibility of the direct cytotoxic action of SB203580
on GH3 cells.
Concluding our study, ang II, ang IV, and ang 5–8
decrease the cell number and proliferation in GH3 cell cul-
ture. The growth-inhibitory eﬀects seem to be dependent on
the direct interaction of ang II with GH3 cells and probably
indirect ang IV action via its degradation product, ang 5–8.
BothERK1/2and p38MAPKpathwaysappeartobeessential
for the growth-regulatory eﬀects of angiotensin peptides in
GH3 cell culture. ERK1/2 participate in the antiproliferative
eﬀect of ang II, whereas p38 MAPK appears to mediate the
inhibitory actions of both ang II and ang 5–8 upon cellular
survival. The mechanism through which ang 5–8 inhibits
proliferation in the GH3 cells remains to be clariﬁed.
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